Business
Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease
ORION CORPORATION PRESS RELEASE 25 APRIL 2025 at 9.00 EEST Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease Orion Corporation (“Orion”) and Criceto IKM B.V. (“Criceto”) today announced the signing of an exclusive license agreement for the development and commercialization of APORON®, a novel apomorphine oromucosal spray for the treatment of OFF episodes in patients with Parkinson’s disease. APORON® is current
About this update from Orion Oyj Class A
[{"type":"image","alt":"Orion Oyj","displaySize":"","headline":null,"caption":"Orion Oyj","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqzIu4PIU0vnnZUA5EUYng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0","width":300,"height":118}},"lazy":false},{"type":"text","content":"ORION CORPORATION PRESS RELEASE 25 APRIL 2025 at 9.00 EEST","length":60,"tagName":"p"},{"type":"text","content":" Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease","length":138,"tagName":"p"},{"type":"text","content":"Orion Corporation (“Orion”) and Criceto IKM B.V. (“Criceto”) today announced the signing of an exclusive license agreement for the development and commercialization of APORON®, a novel apomorphine oromucosal spray for the treatment of OFF episodes in patients with Parkinson’s disease. APORON® is currently in Phase 3 development by Criceto.","length":341,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Orion will be granted an exclusive license to Criceto’s proprietary oromucosal apomorphine spray, in all global markets excluding the United States and Canada. The treatment is designed as a rescue treatment therapy to address OFF episodes—a challenging aspect of Parkinson’s disease that significantly impacts a patient’s quality of life.","length":373,"tagName":"p"},{"type":"text","content":"As part of the agreement, Criceto will receive upfront payments, reimbursements for development costs, and royalties on future commercial sales.","length":144,"tagName":"p"},{"type":"text","content":"“We are excited to enter this collaboration with Criceto,” said Hao Pan, Executive Vice President, Branded Products at Orion. “At Orion, we are committed to improving the lives of patients living with Parkinson’s disease. Our aim is to have treatment options for all stages of the disease and want to help patients every step of their way.”","length":340,"tagName":"p"},{"type":"text","content":"“This partnership leverages Criceto’s expertise in developing advanced rescue treatments for Parkinson’s disease,” said Dr. Bert Tuk...